New Websites Online
Successful Approval of manufacturing and laboratory facilities by Saudi Food and Drug Authority
As the allergy season is starting, we at TIEFENBACHER PHARMACEUTICALS are thrilled to announce that we have successfully prepared the launch of the antihistamine Bilastine for a market entry as Over-the-counter (OTC) medicine in Germany.
We are excited to announce that our two manufacturing sites at AET Laboratories in Hyderabad (India) and at Delorbis in Lefkosia (Cyprus) have been successfully registered by the United Arab Emirates Ministry of Health! The approvals are based on our existing European and international certifications and follow Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!
We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are excited to share that we have successfully prepared the launch of the generic version of Apremilast for a market entry on day one after patent expiration in Canada.
CPhI 2022, the world`s leading pharma event, has just come to an end. It was wonderful to meet our valued customers and partners in person again. Our experts enjoyed three very successful days full of exciting meetings and inspiring discussions. It was a great pleasure to present TIEFENBACHER GROUP´s latest ideas to make pharmaceuticals more affordable, more available, and better than before.
Did you know that TIEFENBACHER GROUP heavily invests in its in-house production capacities? We are excited to announce that our new manufacturing site in Cyprus was ceremoniously opened in mid-October. The “Delorbis” plant is one of the most modern pharmaceutical production site in the European Union. Its facilities are equipped with state-of-the art technologies for the manufacturing of oral dosage forms. This investment follows TIEFENBACHER GROUP´s strategy to strengthen its position as a global, fully integrated pharmaceutical company.
TIEFENBACHER GROUP and OnDosis are thrilled to announce the launch of OYSTA®. The new healthcare brand represents the cooperation initiated in September 2020, including the co-development portfolio of innovative products in five indications. OYSTA® aims to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and flexible dosing.
We at TIEFEENBACHER PHARMACEUTICALS are driven by enabling people around the world a better access to more affordable high-quality medicines. That´s why we are happy to share that we have successfully prepared the launch of the generic version of Apixaban for an early market entry in Canada.
Explore our new booth representing Tiefenbacher Group as a global health pioneer and discover our latest product portfolio and innovations in the field of raw materials, finished dosage forms, and medical devices! Get in touch with our experts to discuss new business opportunities and ideas for improving the life of millions of patients worldwide!